Streamlined Medicare Access to Breakthrough Devices through RAPID Pathway
The Centers for Medicare & Medicaid Services (CMS), together with the U.S. Food and Drug Administration (FDA), has launched the RAPID coverage pathway to streamline Medicare access to Breakthrough Devices designated as Class II and Class III by the FDA. This initiative enhances collaboration between CMS and the FDA, allowing these federal agencies to engage with device developers earlier in the product development stage, aiming to expedite both regulatory review and Medicare coverage determinations.
Dr. Mehmet Oz, CMS Administrator, stressed the significance of early cooperation between agencies to reduce procedural barriers for innovators, thereby facilitating faster access to transformative health technologies for patients. FDA Commissioner Marty Makary highlighted the shared goal of ensuring timely and effective treatment options without procedural delays, committing to a concerted effort to accelerate the delivery of approved Breakthrough Devices to beneficiaries.
The RAPID coverage pathway involves close collaboration among CMS, the FDA, and device manufacturers, focusing on critical clinical outcomes relevant to Medicare beneficiaries. It opens eligibility to certain Class II devices under the FDA's Total Product Life Cycle Advisory Program (TAP) and all Class III devices that meet specific criteria, such as participation in an Investigational Device Exemption (IDE) study with Medicare beneficiaries and pre-approved clinical outcomes.
This approach seeks to leverage premarket evidence effectively, offering informed decisions in both the FDA's regulatory review and Medicare's coverage assessment. By setting evidence expectations earlier, the pathway aims to reduce redundant efforts, enhance procedural efficiency, and provide greater transparency for device innovators.
A crucial feature of this pathway is the synchronization of FDA market authorization with CMS's National Coverage Determination (NCD) process. For devices in the RAPID pathway, CMS will propose an NCD on the day of FDA market authorization, followed by the statutory 30-day public comment period. This streamlined procedure could lead to Medicare coverage decisions within two months post-authorization, significantly faster than the existing timelines.
While the RAPID pathway offers a new option, CMS remains committed to maintaining multiple avenues for medical technology access, preserving the standard channels for reviewing national coverage determinations. The focus on implementing this pathway will temporarily pause new entries into the Transitional Coverage for Emerging Technologies (TCET) Pathway. Feedback from RAPID's implementation will guide ongoing improvements in Medicare coverage processes.
Details on submitting public comments about the RAPID coverage pathway will be announced in an upcoming procedural notice in the Federal Register, marking the start of public engagement with the initiative. The effective date of the pathway depends on the publication of the final notice. Industry stakeholders should monitor the Federal Register for further developments and instructions on participating in the discussion.